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ABSTRACT  
The organic cation transporters OCT and OCTN have been reported to play a significant role 
in the cellular uptake of substrates within in vitro lung cells. However, no studies to date have 
investigated the effect of these transporters upon transepithelial absorption of substrates into 
the pulmonary circulation. We investigated the contribution of OCT and OCTN transporters 
to total pulmonary absorption of L-carnitine and the anti-muscarinic drug, ipratropium, across 
an intact isolated perfused rat lung (IPRL).  The results obtained from the IPRL were 
contrasted with active transport in vitro using three human pulmonary cell lines and primary 
rat alveolar epithelial cells. Ex-vivo studies showed that OCT/OCTN transporters do not play 
a role in the overall pulmonary absorption of L-carnitine or ipratropium, as evidenced by the 
effect of chemical inhibition of these transporters upon pulmonary absorption. In contrast, in-
vitro studies showed that OCT/OCTN transporters play a significant role in cellular 
accumulation of substrates with preferential uptake of ipratropium by OCTs, and of L-
carnitine uptake by OCTNs. The results show that in-vitro uptake studies cannot be predictive 
of airway to blood absorption in-vivo. Nevertheless, localised submucosal pulmonary 
concentrations of inhaled drugs and their pulmonary pharmacodynamic profiles may be 
influenced by OCT/OCTN transport activity. 
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1. Introduction 
A number of drug candidates for inhaled therapy are cationic and are therefore potential 
substrates for the SLC22 superfamily of ATP-independent polyspecific cation transporters at 
the plasma membrane [1]. These transporters include the bidirectional organic cation 
transporters OCT 1 (SLC22A1), OCT2 (SLC22A2), OCT3 (SLC22A3) and the sodium-
dependent carnitine/cation transporter proteins OCTN1 (SLC22A4) and OCTN2 (SLC22A5).  
The majority of inhaled drugs must cross the rate-limiting pulmonary epithelial barrier to 
access their pharmacological targets [2], e.g. smooth muscle cells. As such the interaction of 
cationic drugs with transporter pathways expressed in pulmonary epithelium may be 
important for drug access to underlying pharmacological targets. Indeed this has been the 
premise of research by a number of groups (reviewed in [3-5]) exploring the expression of 
OCTs/OCTNs within lung epithelium.  
The localisation of OCT/OCTN transporters within intact lung has been reported using 
protein immunohistochemistry in both humans [6-9] and rodents [6, 8, 10, 11]. Evidence for 
expression of OCT and OCTN family members in intact human and rat lung tissue also exists 
at the mRNA level [6, 8, 11-13]. Nakanishi et al. [14] showed OCT/OCTN driven 
accumulation of ipratropium in lung epithelial tissue, namely tracheal epithelium, following 
drug deposition in the tracheal lumen of the mouse.  A number of in vitro cell culture studies 
have reported substrate uptake via OCTs and OCTNs in lung epithelial cells including the 
active uptake of the model OCT/OCTN cationic substrate (4-(4-dimethylaminostyryl)-N-
methylpyridinium; ASP
+
) in normal human bronchial cells [7] and in a range of human 
bronchial epithelial cell lines [15-17]. The inhaled anti-muscarinic drug ipratropium has been 
implicated as a substrate of both OCTN and OCT transporters depending upon the in vitro 
model adopted [18, 19].  One report exists of the facilitative role of organic cation 
transporters upon the absorptive and secretory transport of ASP
+
 across a cell monolayer [15] 
with the results showing modest effects upon the overall absorptive transport, despite a 
significant extent of cellular uptake.  
Here we hypothesized that in a fully intact lung the OCT/OCTN transporters play little or no 
role in the transepithelial transport of substrates into the pulmonary vasculature.  To test the 
hypothesis we examined in an intact perfused rat lung (IPRL) the role of OCT/OCTN 
transport in pulmonary transepithelial permeability of the zwitterionic substrate, L-carnitine, 
and the inhaled therapeutic cationic drug, ipratropium; archetype substrates for the pathways 
under study. We found the overall solute transport into the IPRL vasculature was 
predominantly driven by non-competitive passive processes that eclipse the net effect of any 
OCT/OCTN-mediated transport.    
2. Materials and Methods 
2.1 Materials 
 
 [
3
H]-ipratropium bromide (70 Ci/mmol) was provided by GlaxoSmithKline (Ware, UK) and 
[
3
H]-L-carnitine hydrochloride (70 Ci/mmol) was from American Radiochemicals Inc. (St. 
Louis, MO). Unlabelled ipratropium, L-carnitine, tetraethylammonium bromide (TEA) and 1-
methyl-4-phenylpyridinium iodide (MPP
+
) were purchased from Sigma-Aldrich (Poole, UK). 
Cell culture media and supplements were from Invitrogen (Paisley, UK) with cell culture 
plastics from Corning Costar (Hemel Hempstead, UK). All other reagents and solvents were 
from Fisher Scientific (Loughborough, UK) or Sigma-Aldrich. PCR primers were designed in 
house and supplied by Invitrogen (Paisley, UK).  
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2.2 Methods 
 
2.2.1 IPRL 
 
All animal experiments adhered to the UK Animal (Scientific Procedures) Act 1986. Rats 
used for all the experiments in this report weighed 250-350g. Animals were normally housed 
with a 12 hour day/night cycle and fed ad libitum until the time of surgery.  
To examine the transport of ipratropium and L-carnitine across an intact pulmonary barrier an 
IPRL preparation was employed as previously described [20, 21]. This model includes an 
intra-tracheal airway dosing technique that utilises a pressurized metered dose inhaler 
(pMDI) reproducibly delivering a high extent (>95%) of deposited solute liquid aerosol dose 
into the lung periphery [22].  Using the pMDI methodology the IPRL was dosed with either 
vehicle control (100 µL saline) or a competitive inhibitor (in 100 µL saline), i.e. either 
unlabeled solute (125 nmol unlabeled L-carnitine or ipratropium) or the selective OCT 
inhibitor (MPP
+
). Twenty minutes later the lungs were similarly dosed with the radiolabeled 
substrate (3 µCi of [
3
H]-L-carnitine or [
3
H]-ipratropium in 100µL saline). At discrete 
timepoints after lung dosing. 200µL samples were collected from the circulating perfusate 
and transferred to scintillation vials for radiochemical analysis.  
 
2.2.2 Mathematical Modelling 
 
Pulmonary pharmacokinetic absorption parameters were calculated by fitting Equation 1 to 
the individual airway to perfusate absorption data using nonlinear regression analysis 
(Micromath Scientist 3.0, Missouri, USA).  
 
      % ݋݂ ݀݁݌݋ݏ�ݐ݁݀ ݀݋ݏ݁ ܾܽݏ݋ݎܾ݁݀ ሺݐሻ =  ͳͲͲ ∙ ݂ ∙ ሺͳ − ݁−�.�ሻ                   Equation 1 
 
Where, f  represents the available fraction to be transported, k is the absorption rate constant 
(min
-1
) and t is time in minutes.   Modelling of the absorption data was not improved by the 
use of more complex models and Equation 1 was deemed the minimum satisfactory model to 
provide precise parameter estimates for k and f.     
 
2.2.3 In-vitro uptake studies 
 
The in vitro active accumulation of substrates of either OCT and/or OCTN transporters, was 
studied in a range of continuous lung epithelial cell lines and primary cultures of rat lung 
epithelium. The human pulmonary adenocarcinoma cell line, A549 [23], and the human 
bronchial epithelial cell line, BEAS-2B, were obtained from ATCC (American Type Culture 
Collection; Manassas, VA). 16HBE14o
-
 cells, generated by transformation of normal 
bronchial epithelial cells, were from Dr D. C. Gruenert (University of California San 
Francisco, San Francisco). Culture of these cells was performed as previously described [24], 
and isolation and primary culture of rat alveolar cells to a type I pneumocyte-like phenotype 
was undertaken as detailed in previous work [25]. 
Solute uptake studies described hereafter were conducted at incubation temperatures of both 
37 ºC and 4 
º
C.   Radiolabelled solute was added to each well (24-well format) containing 
confluent cell monolayers. The dosings were 1 µCi (15 pmol) [
3
H]-ipratropium or 1 µCi (15 
pmol) [
3
H]-L-carnitine giving a final radiolabel probe concentration in each well of 50 nM 
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(300 L volume per well).  Time- and temperature-dependent solute uptake was quantified at 
discrete timepoints over a 60 min incubation.  
Radiolabelled solute uptake studies were also undertaken in the presence of unlabelled 
OCT/OCTN competitive inhibitors applied to the cells for a 30 min pre-incubation period 
prior to addition of the radiolabel probes.  The unlabelled inhibitors were used to achieve 
concentrations of 500µM ipratropium, 100µM L-carnitine, 500µM MPP
+
, 5mM TEA; a no-
treatment control comprised radiolabeled solute alone in serum-free DMEM.  Following the 
pre-incubation period, either [
3
H]-ipratropium or [
3
H]-L-carnitine was added to each well and 
the uptake of radiolabel allowed to proceed over a 60 min incubation period.   The solute 
uptake experiments were terminated by two washes of the cell monolayers with ice-cold PBS 
followed by the addition of ice-cold trypsin-EDTA for 5 min, after which the cells were 
harvested and suspended in ice-cold DMEM and centrifuged (4 °C, 200 g) for 10 min after 
which the supernatant was discarded and the cell pellet collected. This cell washing 
procedure was performed three times in total. The resulting cell pellets were transferred to 
scintillation vials and mixed with 3mL of BioSafe 3 scintillation fluid and the cell-associated 
radioactivity quantified by liquid scintillation counting.   The sodium-dependent nature of 
solute uptake for both [
3
H]-ipratropium and [
3
H]-L-carnitine was similarly conducted but 
using an incubation buffer where Na
+
 was isotonically replaced with N-methyl-glucamine as 
previously described [7].  
 
2.2.4 Real-time Quantitative Polymerase Chain Reaction (qPCR) 
Human OCT (SLC22A1, SLC22A3, SLC22A3), human OCTN (SLC22A4, SLC22A5), rat 
OCT (Slc22a1, Slc22a2, Slc22a3) and rat OCTN (Slc22a4, Slc22a5) mRNA sequences were 
aligned using BLAST2  and  the NCBI nucleotide gene search used to identify single exon 
regions; Oligocalc was used to validate all used transcription variants.  Table 1 shows the 
primer sequences used in qPCR experiments.  Total RNA was isolated (RNeasy, Qiagen, 
UK) from pulmonary epithelial cells (A549, BEAS-2B, 16HBE14o
-
 or primary rat alveolar 
epithelial cells) grown under the same conditions as used in the solute uptake experiments.  
Total RNA was also isolated from whole rat lung and liver tissue, with the liver serving as a 
positive control that is known to express OCT/OCTN, albeit at different relative amounts. 
cDNA synthesis was performed via reverse transcription using M-MLV reverse transcriptase 
(Invitrogen, UK) using generic random oligonucleotide (pdN6) primers and quantified  
spectrophotometrically at 260 and 280 nm by GeneQuant.  The cDNA was amplified as 
described elsewhere [26]. qPCR was performed by SYBR
®
 Green chemistry using a DNA 
Engine Opticon 2 Real-Time Cycler (BioRad, UK), previously described elsewhere [27]. The 
increase in fluorescence emission associated with DNA amplification was calculated 
throughout the run of 40 cycles and the cycle number at which fluorescence emission first 
reaches exponential phase was recorded.   
 
3. RESULTS 
3.1 Pulmonary transepithelial transport of [
3
H]-ipratropium and [
3
H]-L-carnitine  
 
We explored if OCT/OCTN-mediated transport was a significant feature in the transepithelial 
absorption (airway to pulmonary vascular space) of [
3
H]-ipratropium and [
3
H]-L-carnitine 
within an intact rat lung.  Over the 60 min IPRL experiment approximately 20% of the lung 
deposited dose of [
3
H]-ipratropium was absorbed to the recirculating vascular perfusate 
(Figure 1A, Table 2) with approximately 3% of [
3
H]-L-carnitine absorbed (Figure 1B, Table 
2). Pre-administration into the airways (20 min prior to that of radiolabelled substrate) of 125 
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nmol of the respective unlabelled solute (either unlabelled ipratropium or L-carnitine) failed 
to significantly alter the extent or rate of absorption of the corresponding radiolabelled 
species. This despite the unlabeled solute dosed at a 3000-fold excess to that of the 
radiolabelled substrate.   Similarly, pre-administration of 125 nmol of MPP
+
 failed to alter 
[
3
H]-ipratroprium absorption profile and kinetics.  None of the above treatments resulted in 
perturbation of pulmonary barrier integrity or permeability as evidenced by the pulmonary 
absorption of the co-administered hydrophilic paracellular probe [
14
C] mannitol remaining 
unaffected (p>0.05) by any treatment (Table 2).   
 
3.2 OCT/OCTN-mediated accumulation of [
3
H]-ipratropium and [
3
H]-L-carnitine by 
primary rat pulmonary epithelial cells  
Real-time qPCR confirmed the presence of Slc22a1-Slc22a5 transcripts in both rat whole 
lung and in primary cultures of rat alveolar epithelial cells (Figure 1C), with the primary 
cultures relatively enriched, with respect to lung tissue, in Slc22a3 and Slc22a4.   As 
expected, we found the uptake of [
3
H]-ipratropium and [
3
H]-L-carnitine by the primary 
alveolar epithelial cells to display temperature dependency (data not shown). Furthermore, 
the accumulation of both solutes was significantly decreased (P < 0.05) by co-incubation with 
their respective unlabelled solute, or in the case of [
3
H]-ipratropium by the OCT inhibitor 
MPP
+ 
(Figure 1D); the effect of MPP
+
 upon L-carnitine uptake was not examined. 
3.3 OCT/OCTN-mediated accumulation of [
3
H]-ipratropium and [
3
H]-L-carnitine by 
human pulmonary cell lines 
We investigated the kinetics and transporter selectivity in the accumulation of [
3
H]-
ipratropium and [
3
H]-L-carnitine using human lung epithelial cell lines (A549, BEAS-2B, 
16HBE14o
-
) constitutively expressing OCT and OCTN transporter proteins. The 
accumulation of both [
3
H]-ipratropium and [
3
H]-L-carnitine (applied at 50 nM) was linear 
over a 60 min period (Supplementary Figure 1) with parallel experiments undertaken at 4 °C 
showing negligible cell-associated radioactivity (< 250 DPM/10
6
 cells at all timepoints; data 
not shown).  The cell lines demonstrated differing capacities to actively accumulate [
3
H]-
ipratropium  and [
3
H]-L-carnitine (Table 3) with all three cell types showing higher (P < 
0.05) levels of accumulation (per 10
6 
cells) for L-carnitine compared to ipratropium.  Of 
particular note was the considerable accumulation (P < 0.05) of [
3
H]-L-carnitine by BEAS-
2B cells, to the extent that 25% of the total applied L-carnitine radiolabel was cell-associated 
at 60 min  
Using qPCR we evaluated solute accumulation by the various lung epithelial cell lines in the 
context of the absolute levels of SLC22A1-SLC22A5 mRNA transcripts in the cells.  Figure 
2A shows the results of the qPCR where the mass of cDNA (femtograms) for each respective 
mRNA transcript is expressed relative to a 2 ng mass of total cDNA.  Consistent with our 
observation of greater cellular accumulation of [
3
H]-L-carnitine in all three cell lines, the 
combined cDNA for SLC22A4 and SLC22A5 was more abundant in each of the three cell 
lines than the respective combined cDNA for SLC22A1, SLC22A2 and SLC22A3.  The 
BEAS-2B cell line showed the highest total SLC22A4 and SLC22A5 levels of all which was 
mirrored by a greater uptake displayed by BEAS-2B for L-carnitine.   
To further explore solute uptake and the interplay between constitutively expressed OCT and 
OCTN transporter proteins we examined the active accumulation of [
3
H]-ipratropium and 
[
3
H]-L-carnitine under challenge by various competitive inhibitors or co-factors (Figures 2B 
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and 2C respectively). Not surprisingly, in all lung epithelial cell lines the accumulation of 
both radiolabelled ipratropium and L-carnitine was significantly (P < 0.05) decreased 
following co-incubation with their respective unlabelled solute. Challenge with unlabelled 
ipratropium resulted in a significant (P < 0.05) reduction of [
3
H]-L-carnitine accumulation in 
all three cell lines (Figure 2C). However, the effect of unlabelled L-carnitine upon [
3
H]-
ipratropium accumulation (Figure 2B)  resulted in a far more restricted response, with a 
reduction  (P < 0.05) in [
3
H]-ipratropium accumulation observed only in the BEAS-2B cells, 
and then only at a marginal level.  Co-incubation of  the highly selective OCT competitive 
inhibitor, MPP
+
, resulted in a significant (P < 0.05) inhibition of [
3
H]-ipratropium 
accumulation in all three cell lines with inhibitory effects most pronounced in A549 cells and 
with the least affected being the BEAS-2B cells (Figure 2B).  Notably MPP
+
 had no 
significant (P > 0.05) effect upon the accumulation of the OCTN substrate [
3
H]-L-carnitine 
(Figure 2C).   Challenge with TEA, a mixed OCT/OCTN inhibitor, resulted in decreases in 
the accumulation of both [
3
H]-ipratropium (Figure 2B) and [
3
H]-L-carnitine (Figure 2C) in all 
three cell lines. OCTN1 and OCTN2 display Na
+
-dependent transport, and in all three lung 
epithelial cell lines the active accumulation of the OCTN substrate [
3
H]-L-carnitine was 
reduced by >90% (P < 0.05) in the absence of Na
+
 (Figure 2C).  In contrast, the accumulation 
of [
3
H]-ipratropium was significantly less dependent on Na
+
 (Figure 2B). Specifically, in the 
absence of Na
+
 no alteration in ipratropium accumulation was observed in A549 cells. In 
BEAS-2B and 16HBE14o
-
 cell lines, Na
+
 depletion had a greater effect on ipratropium 
uptake (25-40% inhibition; P < 0.05), that L-carnitine accumulation.   An MTT assay 
substantiated that none of the competitive inhibitors had any detrimental effect upon in vitro 
cell viability over the time course of experimentation (data not shown).   
4. Discussion 
The objective of this work was to examine the hypothesis that OCT and OCTN transporters 
play little or no role in the absorption of respective archetype substrates into the pulmonary 
circulation of a fully intact lung model. This set of experiments compliments a number of in-
vitro lung epithelial cell-based studies which infer that these transporters may fulfill a role in 
substrate access to sub-mucosal smooth muscle targets.   
Here we used an IPRL system to study transepithelial absorption from the airways, a  fully 
intact whole lung model retaining the relevant in-vivo biological architecture and the various  
sequential and parallel, e.g. paracellular, active/facilitative and passive transcellular routes 
that may contribute to various extents a substrate’s overall transepithelial  penetration. We 
have previously demonstrated that the IPRL can serve as a reliable and robust model that is 
capable of discriminating active transport pathways for substrate movement across lung 
epithelia.  For example, we have shown in the IPRL that P-glycoprotein (P-gp) drug efflux 
reduces the pulmonary absorption of certain P-gp substrates [28], an efflux mechanism which 
can be inhibited in the IPRL by co-administration of the chemical inhibitors such as elacridar 
(GF-120918).  The IPRL displays similar airway perfusion characteristics to the fully intact 
in-vivo rat lung [29-31]. Indeed, in the IPRL the entire lung parenchyma from the secondary 
bronchi (second airway bifurcation) to the deep alveolar regions is perfused by the pulmonary 
circulation [30], as it is in vivo.  
The IPRL experiments (Figs 1A,B) demonstrate a non-saturable transport pathway for 
ipratropium and carnitine, as well as the absence of any demonstrable inhibition of 
ipratropium transport by MPP
+
.  This demonstrates that the OCT and OCTN transporters 
played no significant quantitative role in the overall transport of the substrates ipratropium 
and L-carnitine across the pulmonary barrier into the pulmonary circulation. This particular 
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question has not previously been addressed. Although published studies have investigated the 
in-vitro cell uptake of OCT/OCTN substrates by pulmonary epithelial cells per se.  
In IRPL experiments radiolabelled [
3
H]-ipratropium and [
3
H]-L-carnitine were administered 
to the airways to achieve intraluminal concentrations at least 10-fold lower than their 
respective Km values (>1 µM) for OCT/OCTN [32]. These intra-luminal concentrations were 
determined to be close to those used in our parallel in-vitro uptake studies. Our calculations 
were based on a rat lung epithelial lining fluid (ELF) volume of 250 - 350 µL [21].  We 
found pre-administration of a 3000-fold excess of the respective unlabelled substrate did not 
alter the pulmonary absorption of either [
3
H]-ipratropium or [
3
H]-L-carnitine. Additionally, 
intra-luminal dosing of high concentration of the OCT inhibitor MPP
+
 concentrations 
(mimicking those used in in-vitro studies) did not influence [
3
H]-ipratropium absorption. 
These findings contrast with those of the in-vitro uptake studies which unequivocally showed 
saturable uptake processes for these substrates into lung epithelial cells. Nakanishi and co-
workers reported that the tracheal accumulation of ipratropium in mice over a 90 second 
period was inhibited by both 0.2 and 1 mM carnitine and 0.1mM MPP+ [14]. Backstrom et al 
[33] exploited a lung slice model to investigate the tissue binding of a number of inhaled drug 
molecules. For ipratropium they reported a bound drug partition coefficient of the cell i.e. the 
ratio of intracellular to extracellular unbound drug concentration of 7.1 and for its derivative, 
tiotropium, a value of 1.1. The authors concluded that OCT/OCTN transporter activity was 
responsible for this active accumulation of ipratropium but not for tiotropium, in spite of 
evidence from an analogous kidney slice model that tiotropium is an OCT substrate [19]. The 
tissue slice models used by Backstrom and others allow for a rapid and reliable investigation 
of bound:unbound drug levels in tissue homogenates. However, the model does not offer 
opportunity to investigate specific transport processes active at the luminal epithelial barrier 
such as airway to blood absorption. The epithelial and multiple sub-mucosal cell types 
distributed across the tissue slice are simultaneously exposed to equal concentrations of drug. 
This does not mimic the lung microenvironment in vivo following drug inhalation and 
therefore does not permit the differentiation of distinct tissue binding sites in the tissue slice. 
Of note, the extent of pulmonary absorption of ipratropium (bioavailability of 20% of lung 
dose absorbed) was significantly greater than the zwitterion, L-carnitine (bioavailability of 
3% of lung deposited dose absorbed) indicating a discrimination in the way the lung handles 
these charged molecules. Differences in tissue/protein binding at the epithelial surface within 
the lung, as dictated by physicochemical parameters such as logP, could serve to limit the 
fraction available for absorption into the pulmonary circulation. This whole lung absorption 
data nonetheless matches the low bioavailability of inhaled ipratropium in man after slow 
inhalation [34] and implies that the majority of the deposited dose remains either in the 
airway lumen or is localised to the lung submucosal tissue wherein lies the target smooth 
muscle cells.  
For the purposes of rigorous investigation we also undertook parallel in-vitro pulmonary 
epithelial cell uptake studies. Consistent with others we found that OCT and OCTN 
transporter proteins play a significant role in the in-vitro epithelial cell uptake of ipratropium 
and L-carnitine. We found that human lung epithelial cell lines displayed differing and 
opposing capacities for active uptake of ipratropium and L-carnitine. For example, BEAS-2B 
cells showing the lowest capacity for ipratropium accumulation but the highest for L-
carnitine, while A549 cells showed the reverse profile suggesting these solutes utilise to some 
extent distinct pathways for their active cellular accumulation. These results were in 
agreement with qPCR studies which showed BEAS-2B cells to have the highest potential for 
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OCTN functionality with the combined  SLC22A4 and  SLC22A5 mRNA transcript levels 
approximately 8500-fold greater than the combined levels of the SLC22A1, SLC22A2 and 
SLC22A3 mRNA transcripts. Although our studies did not seek to directly correlate mRNA 
expression levels with transporter functionality in these cells lines it was noticeable that high 
levels of SLC22A4 and SLC22A5 mRNA in BEAS-2B matched the extensive accumulation of 
L-carnitine. We do not exclude however the contribution of another uptake transporter in L-
carnitine uptake. Similar observations have been made by Nakamura et al. [18], who reported 
high expression of OCTN mRNA and a lack of OCT(1-3) mRNA in BEAS-2B cells using 
semi-quantitative PCR. In contrast, Ingoglia et al [35] recently indicated that OCT3 and 
OCT1 could play a role in the uptake of MPP
+
 in BEAS-2B cells; a cell line which, in our 
hands, demonstrated negligible OCT3 expression by qPCR.  
In vitro studies using overexpression kidney cell systems have shown ipratropium to 
variously be a substrate for either OCT [19]  or OCTN transporters [18]. Consistent with 
these reports we show in the human respiratory cell lines, under conditions of constitutive 
expression and allowing for interplay between the transporter subfamilies, that ipratropium 
serves as a transport substrate for both OCT and OCTN but with preference for the former.  
This is exemplified by Na
+
-free incubations, probing OCTN transporter function in 
particular, that revealed dramatic reductions in the uptake of the OCTN substrate L-carnitine 
in all the tested cell lines. Under the same conditions an appreciably smaller effect upon the 
uptake of ipratropium was observed, with uptake in the A549 cell line (displaying the highest 
relative OCT transcript levels) remaining unaffected by the absence of Na
+
.  Consistent with 
the above the OCT selective inhibitor, MPP
+
, had no effect on L-carnitine uptake but resulted 
in significant MPP
+
-mediated inhibition of ipratropium accumulation;  the less profound 
MPP
+
-mediated inhibition of ipratropium accumulation in BEAS-2B cells reflecting the 
considerably higher OCTN expression level in these cells that provides for a compensatory 
uptake. This latter point was reinforced by experiments involving co-incubation with excess 
unlabelled L-carnitine which reduced [
3
H]-ipratropium accumulation only in the ‘OCTN-
dominant’ BEAS-2B cells; a result that is in agreement with Nakamura et al. [18].  
Primary cultures of rat lung alveolar epithelial cells display the phenotypic and biochemical 
hallmarks of the in-vivo type-I pneumocyte, which presents the major constituent (95% 
surface area) of the lung epithelial barrier. In these cultures we found expression of 
OCT/OCTN family members and demonstrated in vitro functionality of these cells in the 
saturable accumulation of both [
3
H]-ipratropium and [
3
H]-L-carnitine; accumulation which 
could be inhibited by co-exposure to their respective unlabelled species, and in the case of 
ipratropium, by the OCT inhibitor, MPP
+
. Other studies in primary rat alveolar epithelial cells 
have reported mRNA for OCT1 and OCT3 [36]  by semi-quantitative PCR, while Miakotina 
et al. [37] observed expression of OCT1 protein in primary rat and mouse alveolar epithelial 
cells.   
It is not currently understood why OCT substrates, such as ipratropium, demonstrate low 
extents of absorption into the pulmonary vasculature in spite of extensive in vitro evidence of 
transporter-facilitated transport into the mucosal epithelia. Unwalla et al [38] reported that the 
transepithelial transport of salbutamol is increased through relaxation of epithelia tight 
junctional complexes that results from the 2-receptor mediated rises in intracellular cAMP 
levels. This mechanism is not expected for ipratropium which acts via the M3 muscarinic 
receptor.  More likely is a complex and dynamic interplay between membrane transporters in 
the epithelial and submucosal lung tissue that serve in concert to limit the access of select 
solutes to the pulmonary vascular bed. 
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5 Conclusions 
In conclusion we find no evidence for a role of OCT/OCTN in the absorption of L-carnitine 
or ipratropium across an intact lung epithelial barrier into the pulmonary circulation. This is 
despite evidence in cell lines, including primary cells from the same group of rats, that the 
transporters play a significant role in the uptake of the substrates in to the epithelial cells. It 
follows that the rate of delivery of such molecules from airspace to lung sub-mucosal tissue 
in the intact organ will predominately be driven by passive processes.  However, it is not 
possible to conclude that OCT and/or OCTN transporters lack influence upon localised 
submucosal pulmonary concentrations, and consequently upon the pharmacodynamic (PD) 
profiles for airway-administered cationic drugs.  Indeed, while OCT and/or OCTN 
transporters may lack significant impact upon the aggregate systemic levels of inhaled 
cationic drug, these transporters may still affect localised drug concentrations (e.g. recycling) 
in the pulmonary PD compartment(s) which is an issue that necessitates further PK/PD 
investigations in the future.  
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Table 1. Sequences of forward and reverse primers used in qPCR analysis of mRNA 
transcript levels in human pulmonary cell lines and rat cells and tissue. 
 
Human  
Protein name Gene name  Primer Sequence  
OCT1 
(SLC22A1) SLC22A1 Forward  5'- GCTCTACTACTGGTGTGTGTGCCGGA 
-
'3 
SLC22A1 Reverse 5'- CTTGCCAGACCTCCCTCAGCCT 
-
'3 
 
     OCT2 
(SLC22A2) SLC22A2 Forward 5'- CGCATCGGACGCCGTTACCC 
-
'3 
SLC22A2 Reverse 5'- CCAGCCAAGCACGCCGAAAAA 
-
'3 
 
    OCT3 
(SLC22A3) SLC22A3 Forward 5'- GGCACGCAGCCCGACCACTA 
-
'3 
SLC22A3 Reverse 5'- CACTGCGCTTGTGAACCAAGCAAAC 
-
'3 
 
    OCTN1 
(SLC22A4) SLC22A4 Forward 5'- GCCTGTCCCCCGGGAACGTT 
-
'3 
SLC22A4 Reverse 5'- AGATTCCACTCGGTCACGACGG 
-
'3 
 
    OCTN2 
(SLC22A5) SLC22A5 Forward 5'- GCCCTATGTAAGGCCAGCCGC 
-
'3 
SLC22A5 Reverse 5'- CTCACACACCAGGTTCCACTCGG 
-
'3 
Rat 
 OCT1 
(SLC22A1) Slc22a1 Forward  5'- GCCTGGCTAAACTGGTGAGGGC 
-
'3 
Slc22a1 Reverse 5'- CGGCCAAACCTGTCTGCAATGTA 
-
'3 
 
   
 
OCT2 
(SLC22A2) Slc22a2 Forward 5'- AGGGSCCATGTCGACCGTGGA 
-
'3 
Slc22a2 Reverse 5'- TTCCGGCCAAACCTGTCCGCTAG 
-
'3 
 
   
 
OCT3 
(SLC22A3) Slc22a3 Forward 5'- AGCGGACAGATACGGCAGGCT 
-
'3 
Slc22a3 Reverse 5'- CGGCAAAGGGAAGGCGTCGT 
-
'3 
 
   
 
 OCTN1 
(SLC22A4) Slc22a4 Forward 5'- CGCCGGACCCCTTTCTCCCAA 
-
'3 
 14 
Slc22a4 Reverse 5'- CAACGATGCTCCGGGGTCCC 
-
'3 
 
   
 
OCTN2 
(SLC22A5) Slc22a5 Forward 5'- GGACGGCATGCGGGACTACG 
-
‘3 
Slc22a5 Reverse 5'- GGATGAACCAGAGAGCCCCA 
-
‘3 
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Table 2. Pharmacokinetic parameters, rate constant (k) and fraction absorbed (f) generated 
from modelling IPRL lung transport data of [3H]-ipratropium and [3H]-L-carnitine. The 
extent of absorption of the control permeability probe 14C-mannitol at 60 minutes is shown 
for comparison. Data are mean ± SD. The number of experimental replicates (n) is shown. 
 
 
Substrate/ 
Treatment 
 
n 
k                                                 
(min-1) 
f                                
(max =1) 
% [14C]-mannitol 
absorbed at 60 
min 
 
[3H] ipratropium  
 
6 0.042 ± 0.028 0.23 ± 0.095 28.5 ± 10.2 
[3H] ipratropium 
+ 125 nmol 
ipratropium 
 
6 0.043 ± 0.017 0.21 ± 0.070 26.6 ±11.5 
[3H] ipratropium 
+ 125 nmol MPP+ 
 
4 0.047 ± 0.022 0.17 ± 0.027 22.8 ±2.3 
[3H] L-carnitine   
 
4 0.054 ± 0.020 0.030 ± 0.023 17.1 ±2.3 
[3H] L-carnitine +    
125 nmol L-
carnitine 
4 0.057 ± 0.030 0.032 ± 0.005 17.3 ± 6.0 
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Table 3 Percentage uptake of [3H]-ipratropium and [3H]-L-carnitine uptake in the three human cell 
lines A549, BEAS-2B and 16HBE14o-. 
 
 
 
  
 Cell Line A549 BEAS-2B 16HBE14o
-
 
% Ipratropium uptake / 10
6
 cells / hr 
 
1.6 ± 0.13 0.23 ± 0.03 0.60 ± 0.04 
% L-carnitine uptake  / 10
6
 cells /  hr 3.4 ± 0.13 25.3 ± 2.0 4.0   ± 0.3 
 17 
Figure 1.  (1A) and (1B):  Cumulative airway to perfusate transport (expressed as % of total 
lung deposited dose) following instillation into the IPRL airways of 45 pmol [
3
H]-
ipratropium or [
3
H]-L-carnitine, respectively. Treatments included: (1A) airway co-
administration of unlabelled (cold) ipratropium (125 nmol) or MPP
+
 (125 nmol) or (1B) 
airway co-administration of unlabelled (cold) L-carnitine (125 nmol). Lines represent the 
predicted transport of each substrate based on mathematical modelling. (1C): Quantitative 
PCR results showing relative levels  of cDNA transcript corresponding to Slc22a1-5 
transporters in whole rat lung tissue, primary rat lung epithelial cells and rat liver (% signal 
expressed to 2 ng total cDNA). (1D):  Uptake (expressed as % of control) at 60 min (37°C) of 
50 nM [
3
H] ipratropium and 50 nM [
3
H] L-carnitine in primary culture rat epithelial cells 
when challenged by pre-incubation with either 500 µM unlabelled ipratropium, 100 µM 
unlabelled L-carnitine, MPP+ (500µM). * Represents statistical significance compared to 
respective control at P<0.05 by one-way ANOVA and Dunnett's post-hoc test.
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Figure 2. (2A): Real-time quantitative PCR results showing amounts of cDNA for OCT1, 
OCT2, OCT3, OCTN1 and OCTN2 mRNA transcripts in the three pulmonary cell lines 
expressed as femtograms / 2ng of total cDNA.  The insert shows the standard curves for gene 
transcripts. (2B) and (2C): % uptake of [
3
H]-ipratropium and [
3
H] L-carnitine in cell lines 
A549, BEAS-2B and 16HBE14o
-
 in the presence and absence of various inhibitors. Data 
shown are mean ± S.D., n=6-8.   * denotes statistical significance (P<0.05) in comparison to 
control (radiolabelled substrate only) using one-way ANOVA with Tukey’s post hoc test. 
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Supplementary Figures  
Fig S1 
Time-dependent accumulation of [3H]-ipratropium (panel A) and [3H]-L-carnitine (panel B) 
in three human lung epithelial cells lines. Cells were incubated at 37°C for pre-determined 
times and harvested for radiochemical analysis as described in the Materials and Methods 
section of the main text. 
 
 
